Rubraca rucaparib

Drug Class

PARP inhibitor

Mechanism

Inhibits poly (ADP-ribose) polymerase (PARP1, PARP2, and PARP3) enzymes, blocking DNA repair pathways and inducing synthetic lethality in BRCA-mutant tumor cells.

Approved Indication

Deleterious BRCA mutation-associated advanced ovarian cancer or recurrent epithelial ovarian cancer, and deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer, per its FDA approval.

What This Means For Patients

Rubraca is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2016) — Sources

Pivotal Clinical Evidence

• TRITON3 — Fizazi et al., N Engl J Med 2023 (NCT02975934) — Sources

Sources

• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209115s000lbl.pdf